AKT1 and neoplasm: Second, GDF15 binds to its receptor GFRAL and activates a chronic inflammatory response via the PI3K/AKT/STAT3 pathway, which induces an imbalance in oxidative stress, resulting in increased tumor burden and drug resistance.